News Hub

Members in the News : MicrofluidX and CCRM Partner on End-to-End Bioprocessing of CAR-T Cell Therapies


MicrofluidX and CCRM Partner on End-to-End Bioprocessing of CAR-T Cell Therapies

Stevenage, UK, and Toronto, Canada, January 11, 2023— MicrofluidX (MFX), a UK-based provider of next-generation bioreactors for cell research and manufacturing, today announced a partnership with CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, to advance manufacturing of lentivirus (LV) CAR-T cells with their next generation platform, the Cyto Engine™.


The project will address the urgent need for higher transduction efficiency, higher homogeneity of the transduced cell population, shorter bioprocessing times, and closed system automation. Early trials (data available here) suggest that primary T-cells can be transduced in the MFX bioreactors with 5x higher efficiency (or 10x lower virus consumption) and 2x more homogeneity than conventional approaches.


“Engineered lentivirus is still the most popular vector for CAR-T gene editing, but current methods consume large amounts of virus, and cells come out with a wide range of vector copy number. This leads to people using non-viral methods, which come with their own challenges. We are very excited about this collaboration because we will be able to show that it doesn’t have to be this way. Virally edited cells in our platform are highly viable, highly transduced, and highly homogeneous, for a fraction of the amount of virus used previously,” said Antoine Espinet, CEO of MicrofluidX.

Access the full press release here.
This press release was written and distributed by CCRM.
For all enquiries, please contact CCRM directly.